- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma ; volume:18 ; number:1 ; day:22 ; month:6 ; year:2020 ; pages:1-16 ; date:12.2020
BMC medicine ; 18, Heft 1 (22.6.2020), 1-16, 12.2020
- Creator
-
García-Romero, N.
Palacín-Aliana, I.
Madurga, R.
Carrión-Navarro, J.
Esteban-Rubio, S.
Jiménez, B.
Collazo, A.
Pérez-Rodríguez, F.
Ortiz de Mendivil, A.
Fernández-Carballal, C.
García-Duque, S.
Diamantopoulos-Fernández, J.
Belda-Iniesta, C.
Prat-Acín, R.
Sánchez-Gómez, P.
Calvo, E.
Ayuso-Sacido, A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12916-020-01610-0
- URN
-
urn:nbn:de:101:1-2020072023003428499282
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- García-Romero, N.
- Palacín-Aliana, I.
- Madurga, R.
- Carrión-Navarro, J.
- Esteban-Rubio, S.
- Jiménez, B.
- Collazo, A.
- Pérez-Rodríguez, F.
- Ortiz de Mendivil, A.
- Fernández-Carballal, C.
- García-Duque, S.
- Diamantopoulos-Fernández, J.
- Belda-Iniesta, C.
- Prat-Acín, R.
- Sánchez-Gómez, P.
- Calvo, E.
- Ayuso-Sacido, A.
- SpringerLink (Online service)
Other Objects (12)
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Does anti-VEGF bevacizumab improve survival in experimental sepsis?
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Does anti-VEGF bevacizumab improve survival in experimental sepsis?
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival
Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis
Bevacizumab and gamma knife radiosurgery for first-recurrence glioblastoma
Re-irradiation of anaplastic meningioma: higher dose and concomitant Bevacizumab may improve progression-free survival
Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial
Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
Does anti-VEGF bevacizumab improve survival in experimental sepsis?
Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
FLAIR-only progression in Bevacizumab-treated relapsing glioblastoma does not predict short survival